TRVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trevi Therapeutics Inc (TRVI) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available. While the stock has potential catalysts and a bullish technical setup, the lack of significant financial growth, recent dilution from a public offering, and neutral trading sentiment suggest waiting for clearer signals or stronger fundamentals before investing.
The stock shows a bullish trend with SMA_5 > SMA_20 > SMA_200 and a positive MACD histogram at 0.104. However, RSI_6 at 50.288 is neutral, and the stock is trading near its pivot level of 14.414. Key support levels are at 13.13 and 12.337, while resistance levels are at 15.697 and 16.49.
The company recently raised $150 million through a public offering, reflecting strong market confidence. Analysts maintain a Buy or Overweight rating, citing attractive entry points and potential impactful catalysts from clinical readouts.
The recent public offering diluted shareholder value, and the financials show no revenue growth, a significant net income loss (-27.15% YoY), and a sharp EPS decline (-45.45% YoY). Trading sentiment from hedge funds and insiders is neutral, and there are no recent signals from Intellectia Proprietary Trading Signals.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$8.32 million (-27.15% YoY), and an EPS drop of -45.45% YoY. Gross margin remains at 0%.
Analysts have lowered price targets slightly (from $25 to $24 and $19 to $18) but maintain Buy and Overweight ratings, citing attractive entry points and potential catalysts from upcoming clinical readouts.
